Want to see AU:PKY full AI Analyst Report?
Top Page
Opyl Ltd.
(Sydney:PKY)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.04
â–²(36.67% Upside)
Action:Reiterated
Date:07/14/26
The score is primarily weighed down by very weak financial performance (sharp revenue decline, persistent losses, negative equity, and ongoing cash burn). Technicals provide only limited support (neutral RSI with oversold Stoch but price still below shorter-term averages), and valuation is constrained by the company being loss-making and offering no dividend yield.
Positive Factors
AI-driven drug discovery
Opyl’s core focus on AI and data-driven methods for drug development aligns with a durable secular shift toward computational R&D in pharma. That capability can create long-term client value, recurring project work and data advantages if the company converts partnerships and IP into repeatable revenue.
Negative Factors
Severe revenue decline
An ~86% YoY top-line drop signals loss of commercial traction or project reductions, undermining prospects for scale. Sustained revenue shrinkage limits ability to move toward break-even, erodes customer confidence, and makes multi-quarter recovery and durable growth more challenging.
Read all positive and negative factors
Positive Factors
Negative Factors
AI-driven drug discovery
Opyl’s core focus on AI and data-driven methods for drug development aligns with a durable secular shift toward computational R&D in pharma. That capability can create long-term client value, recurring project work and data advantages if the company converts partnerships and IP into repeatable revenue.
Read all positive factors
Opyl Ltd. (PKY) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$53.45M
Dividend YieldN/A
Average Volume (3M)1.13M
Price to Earnings (P/E)―
Beta (1Y)1.94
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees5
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,242,970,600
10 Day Avg. Volume406,454
30 Day Avg. Volume1,132,050
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-21.63
Price to Sales (P/S)208.90
P/FCF Ratio-4.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Opyl Ltd. Business Overview & Revenue Model
Company Description
Pathkey.AI Ltd is an Australian digital health firm that harnesses artificial intelligence (AI) to advance clinical trials and improve the predictability of patient outcomes, particularly within Australia. The company presents a suite of AI-driven...
How the Company Makes Money
null...
Opyl Ltd. Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -3.95K | 27.78K | 397.64K | 397.64K | 617.91K | 902.41K |
| Gross Profit | -490.89K | -778.89K | -1.40M | -1.86M | -930.36K | -809.62K |
| EBITDA | -1.89M | -1.66M | -2.68M | -1.70M | -2.27M | -1.14M |
| Net Income | -1.44M | -1.45M | -3.13M | -3.13M | -1.73M | -2.09M |
Balance Sheet | ||||||
| Total Assets | 881.60K | 513.28K | 411.60K | 411.60K | 709.58K | 979.22K |
| Cash, Cash Equivalents and Short-Term Investments | 580.84K | 436.90K | 374.64K | 452.88K | 786.33K | 2.32M |
| Total Debt | 0.00 | 411.73K | 0.00 | 300.00K | 300.00K | 0.00 |
| Total Liabilities | 356.22K | 781.65K | 501.76K | 501.76K | 712.21K | 314.75K |
| Stockholders Equity | 525.39K | -268.37K | -90.16K | -403.59K | 267.01K | 2.19M |
Cash Flow | ||||||
| Free Cash Flow | -1.12M | -1.29M | -2.07M | -1.37M | -1.53M | -918.13K |
| Operating Cash Flow | -1.12M | -1.28M | -2.06M | -1.36M | -1.52M | -903.65K |
| Investing Cash Flow | -332.70K | -334.02K | -17.71K | -2.22K | -2.22K | -14.48K |
| Financing Cash Flow | 1.44M | 1.35M | 2.00M | 1.03M | 1.03M | 2.43M |
Opyl Ltd. Technical Analysis
Negative
0.03
Price Trends
0.05
Negative
0.04
Positive
0.03
Positive
Market Momentum
>-0.01
Positive
39.43
Neutral
6.15
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PKY, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.05, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.43 is Neutral, neither overbought nor oversold. The STOCH value of 6.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PKY.
Opyl Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$489.37M | 30.05 | 22.19% | 0.88% | 16.76% | 50.77% | |
67 Neutral | AU$130.33M | 33.45 | 4.37% | ― | 36.43% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$37.79M | -6.00 | -14.19% | ― | 0.03% | -5.85% | |
48 Neutral | AU$126.59M | -6.03 | -226.75% | ― | 29.37% | -10.38% | |
41 Neutral | AU$53.45M | -8.18 | -1122.02% | ― | ― | ― | |
40 Underperform | AU$10.85M | -0.17 | -209.68% | ― | -71.80% | -1044.71% |
* Healthcare Sector Average
AU:PKY
Opyl Ltd.
0.04
0.02
110.53%
AU:CGS
Cogstate Ltd
2.78
1.08
63.53%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.16
-0.09
-36.00%
AU:BMT
Beamtree Holdings Ltd
0.12
-0.15
-55.56%
AU:AHE
MedAdvisor Limited
0.02
-0.04
-70.69%
AU:ALC
Alcidion Group Limited
0.10
>-0.01
-4.00%
Opyl Ltd. Corporate Events
Pathkey.AI issues 38.7 million new shares under compliance notice
Jul 10, 2026
Pathkey.AI Ltd has issued 38,654,492 fully paid ordinary shares on 10 July 2026, identified on the ASX under the code PKY. The issuance was conducted without a formal disclosure document under the capital raising provisions of the Corporations Act...
Pathkey.ai Plans New Placement of Options and Shares on ASX
Jul 10, 2026
Pathkey.ai Ltd has notified the ASX of a proposed securities issue comprising up to 30 million options and 2 million ordinary fully paid shares. The instruments are to be issued by way of a placement or similar structure, with a proposed issue dat...
Pathkey.ai Seeks ASX Quotation for 38.7 Million New Shares
Jul 10, 2026
Pathkey.ai Ltd, an ASX-listed technology company trading under the code PKY, focuses on artificial intelligence solutions and digital platforms targeting enterprise and data-intensive applications. Its operations reflect the broader growth trend i...
Pathkey.AI Issues New Shares Under Disclosure Exemption
Jun 30, 2026
Pathkey.AI Ltd has issued 34,738,333 fully paid ordinary shares on 30 June 2026, identified on the ASX under code PKY. The shares were issued without a disclosure document, relying on provisions of the Corporations Act that allow certain placement...
PathKey.AI Seeks ASX Quotation for 3.1 Million New Shares
Jun 30, 2026
PathKey.AI Ltd., an ASX-listed artificial intelligence technology company trading under the code PKY, develops AI-based tools and platforms aimed at improving data analysis and decision-making for corporate and institutional customers. The busines...
Pathkey.AI Issues 562.5 Million New Shares Under Disclosure Exemption
Jun 23, 2026
Pathkey.AI Ltd, an ASX-listed technology company trading under the code PKY, operates within the Australian regulatory framework that governs listed entities. The business complies with corporate reporting and continuous disclosure rules, undersco...
PathKey.AI pitches sovereign AI-native chip design in new investor briefing
Jun 23, 2026
PathKey.AI Ltd has released an investor presentation positioning itself as a specialist in sovereign chip design and AI-native technologies amid surging global demand for semiconductors in consumer and industrial devices. The company underscores t...
Pathkey.AI completes Chipforge acquisition to extend AI platform into semiconductor design
Jun 23, 2026
Pathkey.AI has completed the acquisition of Singapore-based Chipforge, an AI-driven semiconductor hardware design specialist, issuing 560 million shares and 150 million performance rights as consideration. The deal adds an AI-powered platform that...
Pathkey.AI grants 8 million performance rights to director Shannon Robinson
Jun 23, 2026
Pathkey.AI has awarded director Shannon Robinson 8 million performance rights via Berger Investment Fund Pty Ltd, an entity she controls, as part of her performance-linked remuneration package. The issue, which carries no cash consideration, follo...
PathKey.ai Issues 150 Million New Unquoted Securities to Expand Equity Base
Jun 23, 2026
PathKey.ai Ltd has notified the market of the issue of 150,000,000 new unquoted securities under terms set out in its notice of meeting, with the securities forming a new class that is not intended to be quoted on the ASX. The capital issuance, pr...
Pathkey.ai Issues 8 Million Unquoted Securities in New Share Classes
Jun 23, 2026
Pathkey.ai has notified the ASX of the issue of 8 million unquoted securities across four new classes, labelled Class A, B, C and D. These securities, which were previously flagged in an earlier capital announcement, are not intended to be listed,...
Pathkey.AI Issues 46 Million Unquoted Performance Rights
Jun 23, 2026
LTD Pathkey.AI has notified the market of the issuance of 46 million unquoted performance rights, comprising equal tranches of Class A, B, C and D securities. These new rights are not intended to be quoted on the ASX and have been issued under pre...
Pathkey.AI Seeks ASX Quotation for 600,000 New Ordinary Shares
Jun 23, 2026
Pathkey.AI Ltd, listed on the Australian Securities Exchange under ticker PKY, operates in the technology sector with an apparent focus on artificial intelligence, though this announcement provides limited detail on its core offerings or customer ...
Pathkey.AI seeks ASX quotation for 560 million new shares
Jun 23, 2026
Pathkey.AI Ltd has applied for quotation of 560,000,000 ordinary fully paid shares on the Australian Securities Exchange under the ticker PKY. The issuance, lodged via an Appendix 2A, marks a substantial expansion of the company’s listed equ...
Pathkey.AI seeks ASX quotation for 1.9 million new shares
Jun 23, 2026
Pathkey.AI Ltd has lodged an application with the ASX for quotation of 1,900,000 ordinary fully paid shares under code PKY. The new securities, issued on June 23, 2026, stem from previously announced transactions and will expand the company’...
PathKey.AI Wins Strong Shareholder Backing for Acquisition and Executive Incentives
Jun 17, 2026
PathKey.AI Ltd has reported that all resolutions put to shareholders at its 17 June 2026 general meeting were passed by the required majority following a poll-based vote. The approvals cover the issue of securities to facilitate an acquisition and...
Pathkey.AI Names Defence-Tech Veteran Andrew Farnsworth CEO to Drive Applied AI Expansion
May 10, 2026
Pathkey.AI has appointed defence and AI systems specialist Andrew Farnsworth as chief executive officer, formalising a role he has effectively played during a six-month strategic review that reframed the company as an applied AI platform provider ...
Pathkey expands agentic AI footprint with Chipforge deal and TrialKey wins
Apr 30, 2026
Pathkey’s March quarter update shows continued investment in developing TrialKey as a scalable, AI-driven tool for clinical trial design, adding a Criteria Optimiser that uses agentic AI workflows to generate and rank protocol options under ...
PathKey.AI links share price surge to confidential Chipforge acquisition talks
Apr 29, 2026
PathKey.AI has responded to an ASX price query after its shares rose from $0.03 to $0.046 and trading volumes spiked in late April. The company disclosed it has been in confidential talks to acquire Singapore-based Chipforge Pte Ltd, which holds a...
Pathkey.AI Shares Halted Ahead of Price Query Response and Acquisition News
Apr 27, 2026
Pathkey.AI has requested and been granted a trading halt on its securities by the ASX, with the suspension to remain in place until the earlier of 29 April 2026 or the release of a pending market announcement. The halt is tied to the company prepa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.